Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 10:17
Editas Medicine Revenue (Quarterly): 0.061M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.061M |
| June 30, 2024 | 0.513M |
| March 31, 2024 | 1.135M |
| December 31, 2023 | 60.05M |
| September 30, 2023 | 5.336M |
| June 30, 2023 | 2.887M |
| March 31, 2023 | 9.851M |
| December 31, 2022 | 6.536M |
| September 30, 2022 | 0.042M |
| June 30, 2022 | 6.362M |
| March 31, 2022 | 6.771M |
| December 31, 2021 | 12.47M |
| September 30, 2021 | 6.197M |
| June 30, 2021 | 0.379M |
| March 31, 2021 | 6.499M |
| December 31, 2020 | 11.42M |
| September 30, 2020 | 62.84M |
| June 30, 2020 | 10.75M |
| March 31, 2020 | 5.723M |
| Date | Value |
|---|---|
| December 31, 2019 | 12.28M |
| September 30, 2019 | 3.848M |
| June 30, 2019 | 2.33M |
| March 31, 2019 | 2.069M |
| December 31, 2018 | 6.119M |
| September 30, 2018 | 14.52M |
| June 30, 2018 | 7.372M |
| March 31, 2018 | 3.927M |
| December 31, 2017 | 3.667M |
| September 30, 2017 | 6.282M |
| June 30, 2017 | 3.097M |
| March 31, 2017 | 0.682M |
| December 31, 2016 | 0.898M |
| September 30, 2016 | 0.962M |
| June 30, 2016 | 3.388M |
| March 31, 2016 | 0.805M |
| December 31, 2015 | 0.792M |
| September 30, 2015 | 0.67M |
| June 30, 2015 | 0.167M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.042M
Minimum
Sep 2022
62.84M
Maximum
Sep 2020
11.41M
Average
6.430M
Median
Revenue (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 133.81M |
| EyePoint Pharmaceuticals Inc | 10.52M |
| Cassava Sciences Inc | -- |
| Adverum Biotechnologies Inc | 1.00M |
| Regenxbio Inc | 24.20M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -62.14M |
| Total Expenses (Quarterly) | 65.73M |
| EPS Diluted (Quarterly) | -0.75 |
| Enterprise Value | -69.45M |
| Profit Margin (Quarterly) | -101.9K% |
| Earnings Yield | -104.9% |
| Normalized Earnings Yield | -104.92 |